bropirimine

Bropirimine (ABPP) is an orally bioavailable pyrimidinone derivative that acts as an immunomodulator and interferon inducer. Developed by the Upjohn Company (now Pfizer), it was primarily investigated for the treatment of superficial transitional cell carcinoma and carcinoma in situ (CIS) of the bladder and upper urinary tract. The drug's mechanism of action involves the activation of Toll-like receptor 7 (TLR7), leading to the induction of endogenous alpha and beta interferons, as well as the stimulation of natural killer (NK) cell activity and macrophage activation. Although bropirimine demonstrated significant clinical activity in Phase II and Phase III trials—particularly in patients who were refractory to or intolerant of Bacillus Calmette-Guérin (BCG) therapy—its development was terminated in the late 1990s after the premature closure of its pivotal intercontinental Phase III study.

Other names

2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone